Search results for "Apalutamide"

showing 2 items of 2 documents

Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review

2021

Abstract Context The assessment of “soft” endpoints such as health-related quality of life (HRQOL) is increasingly relevant when evaluating the optimal treatment sequence of novel therapeutic options in patients with advanced prostate cancer (PCa). Objective To systematically review contemporary data regarding HRQOL outcomes in patients with advanced PCa. Evidence acquisition A systematic review of the literature published between January 2011 and March 2019 was performed using the PubMed/Medline Database. In total, 873 articles were screened, and 14 articles including 12 661 patients were selected for synthesis and included in the current analysis according to the Preferred Reporting Items…

MaleOncologymedicine.medical_specialtyUrologyHealth-related quality of lifeAbiraterone Acetate030232 urology & nephrologyContext (language use)Androgen deprivation therapy03 medical and health scienceschemistry.chemical_compoundMetastatic prostate cancer0302 clinical medicineQuality of lifeInternal medicineHumansMedicineEnzalutamideEuropean Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCastration-resistant prostate cancerbusiness.industryAdvanced prostate cancerApalutamideAbiraterone acetateFunctional Assessment of Cancer Therapy-ProstateAndrogen AntagonistsAdvanced prostate cancer; Castration-resistant prostate cancer; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; European Quality of Life 5-Dimensions; Functional Assessment of Cancer Therapy-Prostate; Health-related quality of life; Metastatic prostate cancerhumanitiesEuropean Quality of Life 5-DimensionsClinical trialProstatic Neoplasms Castration-ResistantSystematic reviewchemistry030220 oncology & carcinogenesisAndrogensQuality of LifebusinessOrchiectomy
researchProduct

Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?

2020

Lately the development of 3 novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of nonmetastatic castration-resistant prostate cancer. After proofing their clinical efficacy in large phase III registration trials with good compatibilities and tolerable side effects currently all 3 substances are Food and Drug Administration-approved in nonmetastatic castration-resistant prostate cancer. The present short review article provides an overview about these new treatment options and discusses their use in daily routine focusing on patient selection as well as on the impact of novel sensitive imaging modalities like pr…

OncologyMalemedicine.medical_specialtyUrology030232 urology & nephrologyHistory 21st Century03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineInternal medicinemedicineEnzalutamideHumansAndrogen Receptor AntagonistsStage (cooking)Adverse effectAgedAged 80 and overbusiness.industryApalutamideMiddle Agedmedicine.diseaseReview articleProstatic Neoplasms Castration-ResistantDarolutamideOncologychemistry030220 oncology & carcinogenesisbusinessUrologic oncology
researchProduct